Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Ulcerative Colitis: Results From a Phase 2a Clinical Trial

• Published in: Journal of clinical gastroenterology Vol. 55; no. 2; p. 134
• Main Authors: Almon, Einat, Shaaltiel, Yoseph, Sbeit, Wisam, Fich, Alex, Schwartz, Doron, Waterman, Mattitiahu, Szlaifer, Mali, Reuveni, Hadar, Amit-Cohen, Bat-Chen, Alon, Sari, Chertkoff, Raul, Paz, Alona, Ilan, Yaron
• Format: Journal Article
• Language: English
• Published: United States 01.02.2021

OPRX-106 is an orally administered BY2 plant cell-expressing recombinant TNF fusion protein (TNFR). Oral administration of OPRX-106 was shown to be safe and effective in inducing favorable anti-inflammatory immune modulation in humans. The current study was aimed at determining the safety and effica...